Treatment of adults with 5q SMA in the Czech Republic

Czech version

Authors: S. Voháňka
Authors‘ workplace: Neuromuskulární centrum ERN, Neurologická klinika LF MU a FN Brno
Published in: Cesk Slov Neurol N 2020; 83/116(Supplementum 2): 5
doi: https://doi.org/10.48095/cccsnn20202S5

Sources

1. Neuromuskulární sekce České neurologické společnosti. [online]. Dostupné z URL: https:/ / www.neuromuskularni-sekce.cz/ .

2. Hagenacker T, Wurster CD, Günther R et al. Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study. Lancet Neurol 2020; 19(4): 317–325. doi: 10.1016/ S1474-4422(20)30037-5.

3. Veerapandiyan A, Eichinger K, Guntrum D et al. Nusinersen for older patients with spinal muscular atrophy: a real-world clinical setting experience. Muscle Nerve 2020; 61(2): 222–226. doi: 10.1002/ mus.26769.

4. Walter MC, Wenninger S, Thiele S et al. Safety and treatment effects of nusinersen in longstanding adult 5q-SMA Type 3 –⁠ a prospective observational study. J Neuromuscul Dis 2019; 6(4): 453–465. doi: 10.3233/ JND-190416.